MAP Pharmaceuticals To Present MAP0004 Phase 2 Clinical Data At The American Headache Society Meeting

Main Category: Headache / Migraine
Also Included In: Conferences;  Clinical Trials / Drug Trials
Article Date: 06 Jun 2007 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster presentation, which was accepted as a late-breaker, is entitled Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo(TM) Inhaler), Poster ID S77, and will be presented on Saturday, June 9, 2007 from 12:00 to 1:00pm CDT. In addition, the Company also has three other poster presentations available for viewing at the conference.

Details for the three presentations are as follows:

-- Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel System (Tempo(TM) Inhaler); Poster ID F07; June 8, 12:30 to 1:30pm CDT.

-- Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo(TM) Inhaler); Poster ID F08; June 8, 12:30 to 1:30pm CDT.

-- (5-HT, Adrenergic, Dopaminergic) Receptor Binding: Implications for Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo(TM) Inhaler); Poster ID S67; June 9, 12:00 to 1:00pm CDT.

MAP Pharmaceuticals is developing a series of inhaled respiratory and systemic drug product candidates delivered with the Tempo inhaler. The first of these product candidates is MAP0004, a systemic migraine treatment designed to provide faster and more consistent relief than current non-injectable therapeutics. In early human studies, MAP0004 delivered therapeutic blood levels within ten minutes of inhalation, similar to those seen only after intravenous injection. This performance will potentially allow MAP0004 to mimic both the efficacy and blood levels of injectable therapy, offering fast relief without injections. By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs of the large, underserved population of migraine sufferers with MAP0004.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and neurological diseases. The Company has announced positive results from Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

MAP Pharmaceuticals, Inc.
http://www.mappharma.com